Blog
RSS FeedPosted by Michael Wonder on 18 Jun 2016
Political parties commit support for community pharmacy model
17 June 2016 - With 17 days until the Federal election, the pharmacy and broader health policies of the political parties ...
Posted by Michael Wonder on 18 Jun 2016
Drug combination for treating skin cancer approved for NHS use
17 June 2016 - Medicines regulator NICE moves at record speed to approve nivolumab for use with ipilimumab in melanoma patients. ...
Posted by Michael Wonder on 17 Jun 2016
Section 100 IVF Program - updated claiming arrangements
17 June 2016 - From 1 July 2016, approved suppliers will be required to submit a Reproductive Technology Accreditation Committee (RTAC) ...
Posted by Michael Wonder on 17 Jun 2016
Cost of cystic fibrosis treatment too high for benefit offered, says NICE
17 June 2016 - NICE has said it will not be able to recommend Orkambi (lumacaftor with ivacaftor, Vertex Pharmaceuticals) for ...
Posted by Michael Wonder on 16 Jun 2016
Sacubitril with valsartan in heart failure: differentiated value added
16 June 2016 - Addendum results in a revised benefit assessment for patients with type 2 diabetes mellitus. ...
Posted by Michael Wonder on 16 Jun 2016
Call for vital Meniere’s disease medication to be added to the PBS
17 June 2016 - Beatrice Tarnawski was walking down bustling Queen Street Mall when the flicker of a shadow on the ...
Posted by Michael Wonder on 16 Jun 2016
NICE publishes appraisal consultation for cobimetinib hemifumarate (Cotellic) for patients with malignant melanoma
16 June 2016 - NICE has published an appraisal consultation for Roche's cobimetinib hemifumarate (Cotellic). ...
Posted by Michael Wonder on 16 Jun 2016
Updated NICE quality standard identifies areas for breast cancer improvement
15 June 2016 - NICE’s latest quality standard published today says people who have been diagnosed with a type of early ...
Posted by Michael Wonder on 16 Jun 2016
Agenda for the 22 June 2016 TC meeting
16 June 2016 - The Transparency Commission will consider the reimbursement of glatiramer acetate (Copaxone), ruxolitinib phosphate (Jakavi), clobazam (Likozam) and ...
Posted by Michael Wonder on 15 Jun 2016
Osimertinib mesylate in lung cancer: no assigned additional benefits
15 June 2016 - No direct comparative studies / effects in historical comparisons too small for statements for additional benefits. ...
Posted by Michael Wonder on 15 Jun 2016
Why cancer can cost more the rarer it is
15 June 2016 - The Pharmaceutical Benefits Scheme is an integral part of the Australian health system. It theoretically provides affordable ...
Posted by Michael Wonder on 14 Jun 2016
Doctor's diary: cancer drugs - hope or hype?
13 June 2016 - When it comes to promoting new cancer therapies, hype springs eternal. But prodigious cost – up to ...
Posted by Michael Wonder on 14 Jun 2016
Medicines information factsheet developed for patients and the public
14 June 2016 - A new information factsheet providing information on how health care professionals decide what medicine is right for ...
Posted by Michael Wonder on 14 Jun 2016
Two new films focus on how SMC works with patient groups
14 June 2016 - To help explain how it works with patient groups to capture and present the patient and carer ...
Posted by Michael Wonder on 14 Jun 2016
NICE recommends laser device to help thousands of men with an enlarged prostate
14 June 2016 - Thousands of men could benefit from laser treatment for an enlarged prostate as recommended in new guidance ...